In patients with unresectable CCA, first-line therapy with gemcitabine/cisplatin plus durvalumab or pembrolizumab is the preferred choice, non-biomarker-stratified, and irrespective of PD1/PD-L1 status. The gene discussed is CD274; the disease is cholangiocarcinoma.